Use and safety of calcium channel blockers in obstetrics

Current Medicinal Chemistry

Volumn 16, Issue 26, 2009, Pages 3330-3340

  Tranquilli, Andrea L ^a   Giannubilo, Stefano R ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Benzodiazepine; Calcium channel blockers; Dihydropyridine; Embryology; Fetus; Hypertension; Phenylalkylamine; Preeeclampsia; Pregnancy; Preterm labour; Safety; Teratology

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATOSIBAN; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; DEACETYLDILTIAZEM; DIHYDRALAZINE; DILTIAZEM; DIPROTEVERINE; HYDRALAZINE; LABETALOL; LACIDIPINE; LIVER ENZYME; NIFEDIPINE; NIMODIPINE; NITRENDIPINE; NORVERAPAMIL; PLACEBO; RITODRINE; SALBUTAMOL; TERBUTALINE; TIAPAMIL; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; BRADYCARDIA; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONSTIPATION; CORONARY ARTERY DISEASE; DIZZINESS; DRUG BILE LEVEL; DRUG BINDING SITE; DRUG COST; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG URINE LEVEL; DYSPNEA; EDEMA; FACE FLUSHING; FATIGUE; FETOTOXICITY; FETUS DISTRESS; FLUSHING; GYNECOLOGY; HEART INFARCTION; HEART MUSCLE CONDUCTION SYSTEM; HEART PALPITATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HELLP SYNDROME; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXIA; LOW DRUG DOSE; LUNG EDEMA; MATERNAL HYPERTENSION; MATERNAL MORTALITY; MEAN ARTERIAL PRESSURE; NAUSEA; NONHUMAN; OBSTETRICS; PERINATAL MORTALITY; PERIPHERAL EDEMA; PREECLAMPSIA; PREMATURE LABOR; REVIEW; SECOND TRIMESTER PREGNANCY; SIDE EFFECT; SMOOTH MUSCLE FIBER; SYSTOLIC HYPERTENSION; TACHYCARDIA; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; UNSPECIFIED SIDE EFFECT; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZODIAZEPINES; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; DIHYDROPYRIDINES; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 70450216823     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709789057699     Document Type: Review

References (161)

1. Katz, A.M.; Hager, W.D.; Messineo, F.C. Calcium channel blockers. Am. J. Med., 1985, 77, 2-10.
2. Vanhoutte, P.M.; Paoletti, R.; Govoni, S. Calcium antagonists: pharmacology and clinical research. Ann. N.Y. Acad. Sci., 1988, 522, 169-182
3. Fleckenstein, A. In Experimental Facts and Therapeutics Prospects, John Wiley, New York, 1983; pp. 286-313.
4. Montuschi, P. In Calcium Antagonists in the Treatment of HYPERTENSION in Pregnancy; Tranquilli AL, Romanini C, Eds.; Parthenon Publishing: New York, 1999; pp. 17-41.
5. Parati, G.; Mancia, G. Calcium antagonists in the treatment of hypertension. Am. Heart J., 1993, 125, 642-648
6. Fleckenstein, A. History of calcium antagonists. Circ. Res., 1983, 52, 1-16.
7. Fleckenstein, A. Calcium Antagonism in Heart and Smooth Muscle: Experimental Facts and Therapeutic Prospects, John Wiley and Sons: New York, 1983.
8. Glossmann, H.; Ferry, D.R.; Goll, A.; Streissnig, J.; Zernig, G. Calcium channels and calcium channel drugs: recent biochemical and biophysical findings. Arzneimittelforschung, 1985, 35, 1917-1935
9. Janis, R.A.; Triggle, D.J. New developments in Ca2+ channel antagonists. J. Med. Chem., 1983, 26, 775-785
10. Nayler, W.G. Calcium Antagonists, Academic Press: London, 1987.
11. Nayler, W.G. Classification and tissue selectivity of calcium antagonists. Zeutschr. Kardiol., 1990, 79, 107-111
12. Spedding, M. Calcium antagonist subgroups. Trends. Pharmacol. Sci., 1987, 6, 109-114
13. Vanhoutte, P.M. The expert committee of the World Health Organization on classification of calcium antagonists. The view of the raporteur. Am. J. Cardiol., 1987, 59, 3A.
14. Opie, L.H. Calcium channel antagonists. Part V: second generation agents. Cardiovasc. Drugs. Ther., 1988, 2, 191-203.
15. Catterall, W.A. Functional subunit structure of voltage-gated calcium channels. Science, 1991, 253, 1499-1500
16. Glossmann, H.; Striessnig, J. Molecular properties of calcium channels. Rev. Physiol. Biochem. Pharmacol., 1990, 114, 1-105.
17. McKenna, E.; Koch, W.J.; Slish, D.F.; Schwartz, A. Towards an understanding of the dihydropyridine-sensitive calcium channel. Biochem. Pharmacol., 1990, 39, 1145-1150 (Pubitemid 20109227)
18. Rampe, T.; Triggle, D.J. New ligands for calcium channels. Trends. Pharmacol. Sci., 1990, 11, 112-115
19. Triggle, D.J. Calcium antagonists: history and perspective. Stroke, 1990, 21, 49-58.
20. Triggle, D.J.; Janis, R.A. Calcium channel ligands. Ann. Rev. Pharmacol. Toxicol., 1987, 27, 347-369
21. Katz, A.M. Molecular basis of calcium channel blockade. Am. J. Cardiol., 1992, 69, l7E-22E.
22. Fozzard, H.A. Mechanisms of pharmacologic intervention at the level of the calcium channel. Am. J. Cardiol., 1992, 69, 4-10.
23. Opie, L.H. Calcium channel antagonists. Part I: fundamental properties, mechanisms, classification, sites of action. Cardiovasc. Drugs. Ther., 1987, 1, 411-430
24. DeWitt, C.R.; Waksman, J.C. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol. Rev., 2004, 23, 223-238
25. Buckley, N.A.; Whyte, I.M.; Dawson, A.H. Overdose with calcium channel blockers. BMJ, 1994, 308, 1639.
26. Olson, K.R.; Erdman, A.R.; Woolf, A.D.; Scharman, E.J.; Christianson, G.; Caravati, E.M.; Wax, P.M.; Booze, L.L.; Manoguerra, A.S.; Keyes, D.C.; Chyka, P.A.; Troutman, W.G.; American Association of Poison Control Centers. Calcium channel blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin. Toxicol., 2005, 43, 797-822.
27. Salhanick, S.D.; Shannon, M.W. Management of calcium channel antagonist overdose. Drug Saf., 2003, 26, 65-79.
28. Kelly, J.; O'Malley, K. Clinical pharmacokinetics of calcium antagonists. An update. Clin. Pharmacokinet., 1992, 22, 416-433
29. Opie, L.H. Clinical Use of Calcium Channel Antagonist Drugs, 2nd ed., Kluwer Academic Publisher: Boston, 1990.
30. ACOG Practice Bulletin. Diagnosis and Management of Preeclampsia and Eclampsia, 2002.
31. Berkowitz, G.S.; Mehalek, K.E.; Chitkara, U.; Rosemberg, J.; Cogswell, C.; Berkowitz, R.L. Doppler umbilical velocimetry in the prediction of adverse outcome in pregnancies at risk for intrauterine growth retardation. Obstet. Gynecol., 1988, 71, 742-746
32. Brar, M.S.; Platt, L.D. Reversed end-diastolic flow velocity on umbilical artery velocimetry in high-risk pregnancies: an ominous finding with adverse pregnancy outcome. Am. J. Obstet. Gynecol., 1988, 159, 559-561
33. Cunningham, F.G.; Lindheimer, M.D. Hypertension in pregnancy. N. Engl. J. Med., 1992, 14, 927-932
34. Davey, D.A.; MacGillivray, I. The classification and definition of the hypertensive disorders of pregnancy. Am. J. Obstet. Gynecol., 1988, 158, 892-897 (Pubitemid 18106884)
35. Gant, N.F.; Pritchard, J.A. In Assessment and Care of the Fetal. Physiological, Clinical and Medicolegal Principles; Eden R.D.; Ed.; Appleton & Lange: Chicago, 1990, pp. 711-723.
36. Walters, B.N.J.; Redman, C.W.G. Treatment of severe pregnancy-associated hypertension with the calcium antagonist nifedipine. Br. J. Obstet. Gynaecol., 1984, 91, 330-336 (Pubitemid 14132439)
37. Seabe, S.J.; Moodley, J.; Becker, P. Nifedipine in acute hypertensive emergencies in pregnancy. S. Afr. Med. J., 1989, 76, 248-250 (Pubitemid 19262979)
38. Fenakel, K.; Fenakel, G.; Appelman, Z. Nifedipine in the treatment of severe preeclampsia. Obstet. Gynecol., 1991, 77, 331-337
39. Tranquilli, A.L.; Rabini, R.A.; Cugini, A.M.; Cester, N.; Valensise, H.; Romanini, C.; Bertoli, E.; Mazzanti, L. Calcium and sodium transport in gestational hypertension. Int. J. Cardiol., 1989, 25, S53-S55.
40. Tranquilli, A.L.; Garzetti, G.G.; De Tommaso, G.; Boemi, M.; Lucino, E.; Fumelli, P.; Romanini, C. Nifedipine treatment in preeclampsia reverts the increased erythrocyte aggregation to normal. Am. J. Obstet. Gynecol., 1992, 167, 942-945
41. Barton, J.R.; Hiett, A.K.; Conover, W.C. The use of nifedipine during the postpartum period in patients with severe preeclampsia. Am. J. Obstet. Gynecol., 1990, 162, 788-792
42. Prevost, R.R.; Akl, S.A.; Sibai, B.M.; Whybrew, W.D. Nifedipine pharmacokinetics in pregnancy-induced hypertension. Pharmacotherapy, 1992, 12, 174-177
43. Raemsch, K.D.; Sommer, J. Pharmacokinetics and metabolism of nifedipine. Hypertension, 1983, 5, 18-24.
44. Tranquilli, A.L.; Conti, C.; Rezai, B.; Garzetti, G.G.; Romanini, C. Nifedipine reduces pressor responsiveness to angiotensin II in pregnant women. Clin. Exp. Obstet. Gynecol., 1994, 21, 45-48 (Pubitemid 24098522)
45. Conti, C.; Tranquilli, A.L.; Garzetti, G.G.; Romanini, C. Modulation of vascular reactivity after acute calcium antagonist administration in pregnant women moderately sensitive to angiotensin infusion. Boll. Soc. Ital. Biol. Sper., 1994, 70, 243-248
46. Pirhonen, J.P.; Erkkola, R.U.; Ekblad, U.U.; Nyman, L. Single dose of nifedipine in normotensive pregnancy: nifedipine concentrations, hemodynamic responses, and uterine and fetal flow velocity waveforms. Obstet. Gynecol., 1990, 76, 807-811 (Pubitemid 20353924)
47. Abalos, E.; Duley, L.; Steyn, D.W.; Henderson-Smart, D.J. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst. Rev., 2007, 24, CD002252.
48. Sibai, B.M. Diagnosis and management of gestational hypertension and preeclampsia. Obstet. Gynecol., 2003, 102, 181-192
49. Report of the National High Blood Pressure Education Program. Working group report on high blood pressure in pregnancy. Am. J. Obstet. Gynecol. 2000, 183, S1-S22.
50. Brown, M.A.; Hague, W.M.; Higgins, J.; Lowe, S.; McCowan, L.; Oats, J.; Peek, M.J.; Rowan, J.A.; Walters, B.N.; Austalasian Society of the Study of Hypertension in Pregnancy. The detection, investigation and management of hypertension in pregnancy: executive summary. Aust. N Z J Obstet. Gynaecol., 2000, 40, 133-138
51. Magee, L.A.; Cham, C.; Waterman, E.J.; Ohlsson, A.; Von Dadelszen, P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ, 2003, 327, 1-10.
52. Berkowitz, G.S.; Papiernik, E. Epidemiology of preterm birth. Epidemiol. Rev., 1993, 15, 414-443
53. Hack, M.; Fanaroff, A.A. Outcomes of children of extremely low birthweight and gestational age in the 1990's. Early. Hum. Dev., 1999, 53, 193-218. (Pubitemid 28556879)
54. Ulmsten, U.; Andersson, K.R.; Wingerup, L. Treatment of premature labor with the calcium antagonist nifedipine. Arch. Gynecol., 1980, 229, 1-5. (Pubitemid 10137093)
55. Csapo, A.I.; Puri, C.P.; Tarro, S.; Henzl, M.R. Deactivation of the uterus during normal and premature labor by the calcium antagonist nicardipine. Am. J. Obstet. Gynecol., 1982, 142, 483-491
56. Bird, L.M.; Anderson, N.C. Jr.; Chandler, M.L.; Young, R.C. The effects of aminophylline and nifedipine on contractility of isolated pregnant human myometrium. Am. J. Obstet. Gynecol., 1987, 157, 171-177 (Pubitemid 17099911)
57. Young, R.C.; Smith, L.H.; McLaren, M.D. T-type and L-type calcium currents in freshly dispersed human uterine smooth muscle cells. Am. J. Obstet. Gynecol., 1993, 169, 785-792
58. Nakajima, H.; Hoshiyama, M.; Yamashita, K.; Kiyomoto, A. Effect of diltiazem on electrical and mechanical activity of isolated cardiac ventricular muscle of guinea pig. Jpn. J. Pharmacol., 1975, 25, 383-392
59. Papatsonis, D.N.; van Geijn, H.P.; Ader, H.J.; Lange, F.M.; Bleker, O.P.; Dekker, G. Nifedipine and ritodrine in the management of preterm labor: a randomised multicentre trial. Obstet. Gynecol., 1997, 90, 230-234
60. Vaast, P.; Dubreucq-Fossaert, S.; Houfflin-Debarge, V.; Provost-Helou, N.; Ducloy-Bouthors, A.S.; Puech, F.; Subtil, D. Acute pulmonary oedema during nicardipine therapy for preterm labour, report of 5 cases. Eur. J. Obstet. Gynaecol., 2004, 113, 98-99.
61. van Geijn, H.P.; Lenglet, J.E.; Bolte, A.C. Nifedipine trials: effectiveness and safety aspects. Br. J. Obstet. Gynaecol., 2005, 112, 79-83.
62. Oei, S.G.; Oei, S.K.; Brolmann, H.A. Myocardial infarction during nifedipine therapy for preterm labour. N. Engl. J. Med., 1999, 340, 154. (Pubitemid 29054860)
63. Bal, L.; Thierry, S.; Brocas, E.; Adam, M.; Van de Louw, A.; Tenaillon, A. Pulmonary edema induced by calcium-channel blockade for tocolysis. Anesth. Analg., 2004, 99, 910-911 (Pubitemid 39100388)
64. Hodges, R.; Barkehall-Thomas, A.; Tippett, C. Maternal hypoxia associated with nifedipine for threatened preterm labour. Br. J. Obstet. Gynaecol., 2004, 111, 380-381
65. Verhaert, D.; Van Acker, R. Acute myocardial infarction during pregnancy. Acta. Cardiol., 2004, 59, 331-339
66. Bracero, L.A.; Leikin, E.; Kirsenbaum, N.; Tejani, N. Comparison of nifedipine and ritodrine for the treatment of preterm labor. Am. J. Perinat., 1991, 8, 365-369
67. Kupferminc, M.; Lessing, J.B.; Yaron, Y.; Peyser, M.R. Nifedipine versus ritodrine for suppression of preterm labour. Br. J. Obstet. Gynaecol., 1993, 100, 1090-1094 (Pubitemid 24003617)
68. Garcia-Velasco, J.A.; Gonzalez Gonzalez, A. A prospective, randomized trial of nifedipine vs ritodrine in threatened preterm labor. Int. J. Gynaecol. Obstet., 1998, 61, 239-244 (Pubitemid 28279641)
69. Carbonne, B.; Tsatsaris, V.J. Which tocolytic drugs in case of preterm labor? Eur. Gynecol. Obstet, Biol. Reprod., 2002, 31, S96-S44.
70. Tsatsaris, V.; Papatsonis, D.; Goffinet, F.; Dekker, G.; Carbonne, B. Tocolysis with nifedipine or beta-adrenergic agonists: a meta-analysis. Obstet. Gynecol., 2001, 97, 840-847 (Pubitemid 32406194)
71. Ray, J.G. Meta-analysis of nifedipine versus beta-sympathomimetic agents for tocolysis during preterm labour. J. SOGC, 1998, 20, 259-269
72. King, J.F.; Flenady, V.J.; Papatsonis, D.N.; Dekker, G.A.; Carbonne, B. Calcium channel blockers for inhibiting preterm labour. Cochrane Database Syst. Rev. 2003, 1, CD002255.
73. Royal College of Obstetricians and Gynaecologists. Tocolytic drugs for women i preterm labour. Clinical Guideline, No.1 (B). 2002.
74. Burgess, A.M.; Vere, D.W. Teratogenic effects of some calcium channel blocking agents in Xenopus embryos. Pharmacol. Toxicol., 1989, 64, 78-82. (Pubitemid 19040255)
75. Harake, B.; Gilbert, R.D.; Ashwal, S.; Power, G.G. Nifedipine: effects on fetal and maternal hemodynamics in pregnant sheep. Am. J. Obstet. Gynecol., 1987, 157, 1003-1008 (Pubitemid 17155146)
76. Childress, C.H.; Katz, V.L. Nifedipine and its indications in obstetrics and gynecology. Obstet. Gynecol., 1994, 83, 616-624
77. Lubbe, W.F. Use of diltiazem during pregnancy. N. Z. Med. J., 1987, 100, 121.
78. Frenkel, Y.; Barkai, G.; Resin, L.; Rath, S.; Mashiach, S.; Battler, A. Pregnancy after myocardial infarction: are we playing safe? Obstet. Gynecol., 1991, 77, 822-825
79. Wilson, A.G.; Kirby, J.D. Successful pregnancy in a woman with systemic sclerosis while taking nifedipine. Ann. Rheum. Dis., 1990, 49, 51-52
80. Colina-Chourio, J.A.; Godoy, N.; Oliveros-Palacios, M.; Villarroel, M.N.; Arocha, I. Successful pregnancy in a severe hypertensive patient treated with nitrendipine: case report. Invest. Clin., 1992, 33, 61-67
81. Broughton-Pipkin, F. In Calcium Antagonists in the Treatment of Hypertension in Pregnancy; Tranquilli, A.L.; Romanini, C.; Eds.; Parthenon Publishing: New York, 1999, pp. 49-59.
82. Manninen, A.; Juhakoski, S.A. Nifedipine concentrations in maternal and umbilical serum, amniotic fluid, breast milk and urine of mothers and offspring. Int. J. Clin. Pharm. Res., 1991, 11, 231-236
83. Belfort, M.A.; Saade, G.R.; Suresh, M.; Johnson, D.; Vedernikov, Y.P. Human umbilical vessels: responses to agents frequently used in obstetric patients. Am. J. Obstet. Gynecol. 1995, 172, 1395-1403.
84. Gopalakrishnan, V.; Park, L.E.; Triggle, C.R. The effect of the calcium channel agonist, Bay K-8644 on human vascular smooth muscle. Eur. J. Pharmacol., 1985, 113, 447-451
85. Mari, G.; Moise, K.J. Jr.; Deter, R.L.; Kirshon, B.; Carpenter, R.J. Doppler assessment of the fetal and uteroplacental circulation during nffedipine therapy for preterm labor. Am. J. Obstet. Gynecol., 1989, 161, 1514-1518
86. Donowitz, M.; Levin, S.; Powers, G.; Elta, G.; Cohen, P.; Cheng, H. Ca2+ channels blockers stimulate ileal and colonic water absorption. Gastroenetrology, 1985, 89, 858-866
87. Valensise, H.; Larciprete, G.; Vasapollo, B.; Novelli, G.P.; Altomare, F.; Andreoli, A.; De Lorenzo, A.; Arduini, D. Nifedipine-induced changes in body composition in hypertensive patients at term. Eur. J. Obstet. Gynecol. Reprod. Biol., 2003, 106, 139-143 (Pubitemid 36120458)
88. Read, M.D.; Wellby, D.E. The use of a calcium antagonist (nifedipine) to suppress preterm labour. Br. J. Obstet. Gynaecol., 1986, 93, 933-937
89. Ferguson, J.E. 2nd.; Dyson, D.C.; Schutz, T.; Stevenson, D.K. A comparison of tocolysis with nifedipine or ritodrine: analysis of efficacy and maternal, fetal, and neonatal outcome. Am. J. Obstet. Gynecol., 1990, 163, 105-111
90. Meyer, W.R.; Randall, H.W.; Graves, W.L. Nifedipine versus ritodrine for suppressing preterm labor. J. Reprod. Med., 1990, 35, 649-653
91. Murray, C.; Haverkamp, A.D.; Orleans, M.; Berga, S.; Pecht, D. Nifedipine for treatment of preterm labor: a historic prospective study. Am. J. Obstet. Gynecol., 1992, 167, 52-56
92. Sibai, B.M.; Barton, J.R.; Akl, S.; Sarinoglu, C.; Mercer, B.M. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am. J. Obstet. Gynecol., 1992, 167, 879-884
93. Childress, C.H.; Katz, V.L. Nifedipine and its indications in obstetrics and gynecology. Obstet. Gynecol., 1994, 83, 616-624
94. Magee, L.A.; Schick, B.; Donnenfeld, A.E.; Sage, S.R.; Conover, B.; Cook, L.; McElhatton, P.R.; Schmidt, M.A.; Koren, G. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am. J. Obstet. Gynecol., 1996, 174, 823-828 (Pubitemid 26111652)
95. Sorensen, H.T.; Czeizel, A.E.; Rockenbauer, M.; Steffensen, F.H.; Olsen, J. The risk of limb deficiencies and other congenital abnormalities in children exposed in utero to calcium channel blockers. Acta. Obstet. Gynecol. Scand., 2001, 80, 397-401. (Pubitemid 32473046)
96. Bortolus, R.; Ricci, E.; Chatenoud, L.; Parazzini, F. Nifedipine administered in pregnancy: effect on the development of children at 18 months. Br. J. Obstet. Gynaecol., 2000, 107, 792-794 (Pubitemid 30311917)
97. Spatz, R.J.; Pillalamari, E.D.; Diab, G.M.; Abadir, A.R.; Gintautas, J. Verapamil effect on fetus in rat. Proc. West. Pharmacol. Soc., 1986, 29, 319-320
98. Murad, S.H.; Tabsh, K.M.; Shilyanski, G.; Kapur, P.A.; Ma, C.; Lee, C.; Conklin, K.A. Effects of verapamil on uterine blood flow and maternal cardiovascular function in the awake pregnant ewe. Anesth. Analg., 1985, 64, 7-10.
99. Yoshida, T.; Kanamori, S.; Hasegawa, Y. Hyperphalangeal bones induced in rat pups by maternal treatment with nifedipine. Toxicol. Lett., 1988, 40, 127-132 (Pubitemid 18032569)
100. Richichi, J.; Vasilenko, P. The effects of nifedipine on pregnancy outcome and morphology of the placenta, uterus, and cervix during late pregnancy in the rat. Am. J. Obstet. Gynecol., 1992, 167, 797-803.
101. Danielsson, B.R.; Danielson, M.; Rundqvist, E.; Reiland, S. Identical phalangeal defects induced by phenytoin and nifedipine suggest fetal hypoxia and vascular disruption behind phenytoin teratogenicity. Teratology, 1992, 45, 247-258
102. Stein, G.; Srivastava, M.K.; Merker, H.J.; Neubert, D. Effects of calcium channel blockers on the development of early rat postimplantation embryos in culture. Arch. Toxicol. 1990, 64, 623-638
103. Leist, K.H.; Grauwiler, J. Fetal pathology in rats following uterine-vessel clamping on day 14 of gestation. Teratology, 1974, 10, 55-68.
104. Kantelip, J.P.; Talmant, J.M.; Duchene-Marullaz, P. Effects of diproteverine, a new calcium antagonist on sinoatriai node and artrioventricular conduction in conscious unsedated dogs. J. Cardiovasc. Pharmacol., 1988, 12, 432-437 (Pubitemid 18219720)
105. Lacroix, P.; Linee, P.; Forest, M.C. Diproteverine (BRL 40015): a new type of calcium antagonist with potential antianginal properties. Eur. J. Pharmacol., 1991, 192, 317-327
106. Ridings, J.E.; Palmer, A.K.; Davidson, E.J.; Baldwin, J.A. Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod. Toxicol., 1996, 10, 43-49. (Pubitemid 2625289)
107. Ban, Y.; Nakatsuka, T.; Matsumoto, H. Effects of calcium channel blockers on cultured rat embryos. J. Appl. Toxicol., 1996, 16, 147-151 (Pubitemid 26112086)
108. Ban, Y.; Makita, T. A calcium agonist, bay k 8644, suppreses the embryotoxic effects induced by dihydropyridines calcium channel blockers in cultured rat embryos. J. Vet. Med. Sci., 1998, 60, 1067-1072 (Pubitemid 128530637)
109. United States of America Freedom of Information Act. Information on nifedipine (FOIA). Review and Evaluation of Preclinical Data; 1981, NDA18-482.
110. Suzuki, M.; Yamanaka, K.; Nabata, H.; Tachibana, M. Long term effects of amlodipine on organ damage, stroke and life span in stroke prone spontaneously hypertensive rats. Eur. J. Pharmacol., 1993, 228, 269-274 (Pubitemid 23093779)
111. Orisakwe, O.E.; Chilaka, K.C.; Afonne, O.J.; Obi, E.; Ilondu, N. Evaluation of the developmental toxicity of amlodipine besylate in mice. J. Health Sci., 2000, 46, 42-45. (Pubitemid 30133803)
112. Murad, S.H.N.; Tabsh, K.M.A.; Conklin, K.; Shilyansk, G.; Ziadlourade, F.; Kapaur, P.A.; Flacke, W.E. Verapamil: placental transfer and effects on maternal and fetal haemodynamics and atrioventricular conduction in the pregnant ewe. Anesthesiology, 1985, 62, 49-53.
113. Bartels, P.; Hanff, L.; Mathot, R.; Steegers, E.; Vulto, A.; Visser, W. Nicardipine in pre-eclamptic patients: placental transfer and disposition in breast milk. BJOG, 2007, 114, 230-233
114. Broughton Pipkin, F.; Lawrence, MR. The effect of nitrendipine (NIT) on maternal and fetal blood pressure, uterine blood flow and blood gas status in pregnant sheep. J. Cardiovasc. Pharmacol., 1988, 12, S123-S125.
115. Danielsson, B.R.; Reiland, S.; Rundqvist, E.; Danielson, M. Digital defects induced by vasodilating agents: relationship to reduction in uteroplacental blood flow. Teratology, 1989, 40, 351-358 (Pubitemid 19271343)
116. Clemmer, T.; Telford, I. Abnormal development of the rat heart during prenatal hypoxic stress. Proc. Soc. Exp. Biol. Med., 1966, 121, 800-803
117. Jaffee, O. The effects of moderate hypoxia and moderate hypoxia with hypercapnea on cardiac development in chick embryos. Teratology, 1974, 10, 275-278
118. Ingalls, T. Environmental factors and teratogenesis. In: Congenital malformations, Wolstenholme, G.; O'Connor, C.; Ed.; Churchill: London, 1960; pp. 51-77.
119. Holbrook, Jr. R.H.; Lirette, M.; Katz, M. Cardiovascular and tocolytic effects of nicardipine HCl in the pregnant rabbit: comparison with ritodrine HCl. Obstet. Gynecol., 1987, 69, 83-87
120. Matsuda, Y.; Ikenoue, T.; Matsuda, K.; Sameshima, H.; Ibara, S.; Hokanishi, H.; Sakamoto, H. The effect of nicardipine on maternal and fetal hemodynamics and uterine blood flow in chronically instrumented pregnant goats. Asia. Oceania. J. Obstet. Gynaecol., 1993, 19, 191-198 (Pubitemid 23251740)
121. Blea, C.W.; Barnard, J.M.; Magness, R.R.; Phernetton, T.M.; Hendricks, S.K. Effect of nifedipine on fetal and maternal hemodynamics and blood gases in the pregnant ewe. Am. J. Obstet. Gynecol., 1997, 176, 922-930
122. Momma, K.; Takao, A. Fetal cardiovascular effects of nifedipine in rats. Pediatr. Res.. 1989, 26, 442-447 (Pubitemid 19267294)
123. Furuhashi, N.; Tsujiei, M.; Kimura, H.; Yajima, A. Effects of nifedipine on normotensive rat placental blood flow, placental weight and fetal weight. Gynecol. Obstet. Invest., 1991, 32, 1-3.
124. De Cesaris, R.; Ranieri, G.; Filitti, V.; Andriani, A. Large artery compliance in essential hypertension. Effects of calcium antagonism and β-blocking. Am. J. Hypertens., 1992, 5, 624-628
125. Robinson, B.F.; Dobbs, R.J.; Kelsey, C.R. Effects of nifedipine on resistant vessels, arteries and veins in man. Br. J. Clin. Pharmacol., 1980, 10, 433-438
126. Kiowski, W.; Erne, P.; Bertel, O.; Bolli, P.; Buhler, F.R. Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine. J. Am. Coll. Cardiol., 1986, 7, 344-348
127. Reams, G.P.; Lau, A.; Bauer, J.H. Short-term and long-term renal response to nifedipine monotherapy. Am. J. Hypertens., 1989, 2, 188-190
128. Zanchetti, A.; Leonetti, G. Natriuretic effect of calcium antagonists. J. Cardiovasc. Pharmacol., 1985, 7, S33-S37.
129. Nayler, W.G. Calcium Antagonists, Academic Press: San Diego, 1989.
130. Caritis, S.N.; Lin, L.S.; Wong, L.K. Evaluation of the pharmacodynamics and pharmacokinetics of ritodrine when administered as a loading dose. On establishing a potentially useful drug administration regimen in cases of fetal distress. Am. J. Obstet. Gynecol., 1985, 152, 1026-1031
131. van Zwieten, P.A.; Pfaffendorf, M. Pharmacology of the dihydropyridine calcium antagonists: relationship between lipophilicity and pharmacodynamic responses. J. Hypertens., 1993, 11, S3-S8. (Pubitemid 24043991)
132. Opie, L.H. Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Prog. Cardiovasc. Dis., 1996, 38, 273-290. (Pubitemid 26035431)
133. Frishman, W.H. Current status of calcium channel blockers. Curr. Probl. Cardiol., 1994, 19, 637-688
134. Weiner, D.A. Calcium channel blockers. Med. Clin. North. Am., 1988, 72, 83-115.
135. Abernethy, D.R. Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist. Am. J. Cardiol., 1997, 80, 4C-11C.
136. Impey, L. Severe hypertension and fetal distress following sublingual administration of nifedipine to a patient with severe pregnancy induced hypertension at 33 weeks. BJOG, 1993, 100, 959-961 (Pubitemid 23308289)
137. Blache, D.; Ojeda, C. Comparative inhibitory effects of dihydropyridines on platelet aggregation, calcium uptake and cyclic AMP concentration. Pharmacology, 1992, 45, 250-259
138. Tschoepe, D.; Homberg, M.; Roesen, P.; Gries, F.A. Reduced platelet thromboxane formation after long-term administration of a dihydropyridine calcium channel blocker: a prospective, double-blind, placebo-controlled study with nitrendipine in borderline hypertensive patients with IDDM-type diabetes mellitus. Diabetes Res., 1992, 19, 125-131
139. Fenakel, K.; Lurie, S. The use of calcium channel blockers in obstetrics and gynecology; a review. Eur. J. Obstet. Gynecol., 1990, 37, 199-203.
140. Begg, E.J.; Atkinson, H.C.; Duffull, S.B. Prospective evaluation of a model for the prediction of milk: plasma drug concentrations from physiochemical characteristics. Br. J. Clin. Pharmacol., 1992, 33, 501-505
141. Barton, J.R.; Prevost, R.R.; Wilson, D.A.; Whybrew, W.D.; Sibai, B.M. Nifedipine pharmacokinetics and pharmacodynamics during the immediate postpartum period in patients with preeclampsia. Am. J. Obstet. Gynecol., 1991, 165, 951-954
142. Foster, T.S.; Hamann, S.R.; Richards, V.R.; Bryant, P.J.; Graves, D.A.; McAllister, R.G. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J. Clin. Pharmacol., 1983, 23, 161-170 (Pubitemid 13131441)
143. WHO. Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs, 2002
144. American Academy of Pediatrics. Committee on drugs transfer of drugs and other chemicals into human milk. Pediatrics, 2001, 108, 776-789
145. American Academy of Pediatrics. Committee on Drugs The transfer of drugs and other chemicals into human breast milk. Pediatrics, 1983, 72, 375-383
146. Okada, M.; Inoue, H.; Nakamura, Y.; Kishimoto, M.; Suzuki, T. Excretion of diltiazem in human milk. N. Engl. J. Med., 1985, 312, 992-993
147. Anderson, P.; Bondesson, U.; Mattiasson, I.; Johansson, B.W. Verapamil and norverapamil in plasma and breast milk during breast feeding. Eur. J. Clin. Pharmacol., 1987, 31, 625-627
148. Ehrenkranz, R.A.; Ackerman, B.A.; Hulse, J.D. Nifedipine transfer into human milk. J. Pediatr., 1989, 114, 478-480
149. Beardomore, K.S.; Morris, J.M.; Gallery, E.D.M. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypert. Pregnancy, 2002, 21, 85-95.
150. Andersen, H.J. Excretion of verapamil in human milk. Eur. J. Clin. Pharmacol., 1983, 25, 279-280
151. Inoue, H.; Unno, N.; Ou, M.C.; Iwama, Y.; Sugimoto, T. Level of verapamil in human milk. Eur. J. Clin. Pharmacol., 1984, 26, 657-658
152. Miller, M.R.; Withers, R.; Bhamra, R.; Holt, D.W. Verapamil and breast-feeding. Eur. J. Clin. Pharmacol., 1986, 30, 125-126
153. Ahn, H.K.; Nava-Ocampo, A.A.; Han, J.Y.; Choi, J.S.; Chung, J.H.; Yang, J.H.; Koong, M.K.; Park, C.T. Exposure to amlodipine in the first trimester of pregnancy and during breastfeeding. Hypertens. Pregnancy, 2007, 26, 179-187 (Pubitemid 46676545)
154. Briggs, G.; Freeman, R.; Yaffe, S. Drugs in Pregnancy and Lactation, Wilkins & Wilkins: Baltimore, 1990.
155. Hartmann, D.; Lunell, O.; Friedrich, G.; Rane, A. Excretion of tiapamil in breast milk. Br. J. Clin. Pharmac., 1988, 26, 183-186
156. Hennessy, A.; Horvath, J.S. Newer antihypertensive agents in pregnancy. Med. J. Aust., 1992, 156, 304-305
157. Thornton, J. The drugs we deserve. Br. J. Obstet. Gynaecol., 2003, 110, 969-970
158. Briggs, G.G.; Freeman, R.K.; Yaffe, S.J. Drugs in pregnancy and lactation, Williams & Wilkins: Baltimore, 1994.
159. Hennessy, A.; Gillin, A.; Horvath, J. Cardiovascular Research in Pregnancy: The Role of Animal Models. Hypertens. Pregnancy., 1993, 12, 413-437 (Pubitemid 24030340)
160. Pratt, R.M. Receptor-dependent mechanisms of gtucocorticoid and dioxin-induced cleft palate. Environ. Health Perspect., 1985, 61, 35-40.
161. Oei, S.G. Calcium channel blockers for tocolysis: A review of their role and safety following reports of serious adverse events. Eur. J. Obstet. Gynecol. Reprod. Biol., 2006, 126, 137-145